SCHEMBL240671

SCHEMBL240671

CC(C)(C)c1ccc(N2[C@H](c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)CC[C@H]2c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LPL P06858 12/20 0.37
LIPG Q9Y5X9 12/20 0.37
HIF1A Q16665 1/20 0.35
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
CA12 O43570 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
RIPK1 Q13546 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
F11 P03951 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240673 1.00 LPL (0.37) LPLLIPGHIF1ACA1CA2
SCHEMBL240672 1.00 LPL (0.37) LPLLIPGHIF1ACA1CA2
SCHEMBL1982346 0.90 HSD11B1 (0.43) HIF1A
SCHEMBL1983458 0.89 LPL (0.35) LPLLIPGHIF1ACA1CA2
SCHEMBL1985257 0.89 LPL (0.38) LPLLIPGCA1CA2CA9
SCHEMBL1985242 0.89 LPL (0.38) LPLLIPGCA1CA2CA9
SCHEMBL18653104 0.86 HIF1A (0.33) HIF1A
SCHEMBL1983656 0.85 LPL (0.40) LPLLIPGHIF1ACA1CA2
SCHEMBL2368378 0.84 LPL (0.55) LPLLIPGCA1CA2CA9
SCHEMBL1982204 0.79 HIF1A (0.36) LPLLIPGHIF1ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 EP disclosed
US-9586978-B2 Anti-viral compounds ABBVIE INC. (US) 2017-03-07 US disclosed
EP-2628481-B1 Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV ABBVIE BAHAMAS LTD (BS) 2016-02-24 EP disclosed
EP-2368890-B1 Hepatitis C virus inhibitors ABBVIE BAHAMAS LTD (BS) 2013-04-17 EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 EP disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
EP-2337781-A2 ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION Abbott Laboratories (US) 2011-06-29 EP disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 US disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LPL 1419/4885LIPG 768/4885HIF1A 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.